Status:
TERMINATED
Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies
Lead Sponsor:
Centre Hospitalier Régional d'Orléans
Conditions:
COVID-19
SARS CoV 2 Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Natural infection, vaccines and treatments (like monoclonal antibodies) lead to the appearance of a neutralizing power in the serum (due to induced or injected antibodies). This neutralizing power is ...
Detailed Description
Infection, vaccines and treatments (like monoclonal antibodies) lead to the appearance of a neutralizing power in the serum (due to induced or injected antibodies). This neutralizing power is recogniz...
Eligibility Criteria
Inclusion
- Adult volunteers for the study, having received or about to receive any intervention inducing or conferring neutralizing anti-SARS-CoV-2 antibodies (vaccines - whatever the mode of action -, monoclonal antibodies).
- Having given their consent to participate in the study
Exclusion
- Minors
- Pregnant women
- Persons under tutorship or curatorship
- Protected adults
- Person under legal protection
- Person not affiliated to a social security scheme
- Persons unable to express their consent
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 16 2023
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT05315583
Start Date
December 1 2022
End Date
March 16 2023
Last Update
November 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Régional d'Orléans, France
Orléans, France, 45000